Abstract
Evasion of apoptosis can be caused by epigenetic silencing of caspase-8, a key component of the extrinsic apoptosis pathway. Loss of caspase-8 correlates with poor prognosis in medulloblastoma, which highlights the relevance of strategies to upregulate caspase-8 to break apoptosis resistance. Here, we develop a new combinatorial approach, that is treatment using histone deacetylase inhibitors (HDACI) together with interferon (IFN)-γ, to restore caspase-8 expression and to overcome resistance to the death-receptor ligand TNF-related apoptosis-inducing ligand (TRAIL) in medulloblastoma in vitro and in vivo. HDACI, for example, valproic acid (VA), suberoylanilide hydroxamic acid (SAHA) and MS-275, cooperate with IFN-γ to upregulate caspase-8 in cancer cells lacking caspase-8, thereby restoring sensitivity to TRAIL-induced apoptosis. Molecular studies show that VA promotes histone acetylation and acts in concert with IFN-γ to stimulate caspase-8 promoter activity. The resulting increase in caspase-8 mRNA and protein expression leads to enhanced TRAIL-induced activation of caspase-8 at the death-inducing signaling complex, mitochondrial outer-membrane permeabilization and caspase-dependent cell death. Intriguingly, pharmacological or genetic inhibition of caspase-8 also abolishes the VA/IFN-γ-mediated sensitization for TRAIL-induced apoptosis. It is important to note that VA and IFN-γ restore caspase-8 expression and sensitivity to TRAIL in primary medulloblastoma samples and significantly potentiate TRAIL-mediated suppression of medulloblastoma growth in vivo. These findings provide the rationale for further (pre)clinical evaluation of VA and IFN-γ to restore caspase-8 expression and apoptosis sensitivity in cancers with caspase-8 silencing and open new perspectives to overcome TRAIL resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout






Similar content being viewed by others
References
Adams JM, Cory S . (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324–1337.
Ashkenazi A . (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19: 325–331.
Ashkenazi A, Herbst RS . (2008). To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979–1990.
Banelli B, Casciano I, Croce M, Di Vinci A, Gelvi I, Pagnan G et al. (2002). Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med 8: 1333–1335.
Blaheta RA, Cinatl Jr J . (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492–511.
Bolden JE, Peart MJ, Johnstone RW . (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784.
Fulda S . (2008). Caspase-8. In: Schwab M (ed). Encyclopedia of Cancer. Springer: Berlin.
Fulda S, Debatin K-M . (2002). IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295–2308.
Fulda S, Debatin KM . (2006a). 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25: 5125–5133.
Fulda S, Debatin KM . (2006b). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798–4811.
Fulda S, Debatin KM . (2006c). Therapeutic modulation of apoptosis in cancer therapy. In: Fulda S, Debatin KM (eds). Apoptosis and Cancer Therapy. Wiley-VCH: Weinheim. pp 515–535.
Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM . (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865–5877.
Fulda S, Meyer E, Debatin KM . (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283–2294.
Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . (1997). The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57: 3823–3829.
Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S . (2005). Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65: 10502–10513.
Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969–6978.
Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR et al. (2000). Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19: 4604–4610.
Guerrini R . (2006). Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 8: 113–129.
Hengartner MO . (2000). The biochemistry of apoptosis. Nature 407: 770–776.
Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C et al. (2003). Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10: 356–364.
Jiang M, Zhu K, Grenet J, Lahti JM . (2008). Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 1783: 1055–1067.
Jonasch E, Haluska FG . (2001). Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34–55.
Krammer PH . (2000). CD95's deadly mission in the immune system. Nature 407: 789–795.
Kroemer G, Galluzzi L, Brenner C . (2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99–163.
Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K et al. (2004). Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90: 535–541.
Li X-N, Shu Q, Su JM-F, Perlaky L, Blaney SM, Lau CC . (2005). Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4: 1912–1922.
Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N et al. (2007). Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 170: 1917–1930.
Meister N, Shalaby T, von Bueren AO, Rivera P, Patti R, Oehler C et al. (2007). Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy. Eur J Cancer 43: 1833–1841.
Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ et al. (2004). Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 64: 8349–8356.
Mohr A, Zwacka RM, Debatin KM, Stahnke K . (2004). A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 11: 1153–1154.
Nightingale KP, O'Neill LP, Turner BM . (2006). Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 16: 125–136.
Ozoren N, El-Deiry WS . (2002). Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (New York) 4: 551–557.
Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH . (1997). Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 27: 1207–1212.
Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T et al. (2003). Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9: 6401–6409.
Roth SY, Denu JM, Allis CD . (2001). Histone acetyltransferases. Annu Rev Biochem 70: 81–120.
Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A . (2000). Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60: 5673–5680.
Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F et al. (2007). Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13: 2651–2657.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675–1687.
Shu Q, Antalffy B, Su JMF, Adesina A, Ou C-N, Pietsch T et al. (2006). Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res 12: 4687–4694.
Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MRM, Yagita H . (2003). Nature's TRAIL—on a path to cancer immunotherapy. Immunity 18: 1–6.
Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ et al. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95–99.
Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529–535.
Tekautz TM, Zhu K, Grenet J, Kaushal D, Kidd VJ, Lahti JM . (2006). Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma—preclinical studies. Biochim Biophys Acta 1763: 1000–1010.
Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF . (2003). Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 983: 84–100.
Van Boxel-Dezaire AH, Stark GR . (2007). Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol 316: 119–154.
Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL et al. (1998). Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9: 267–276.
Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S . (2007). Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26: 248–257.
Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68: 7956–7965.
Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. (2009). Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69: 2425–2434.
Wagner KW, Engels IH, Deveraux QL . (2004). Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem 279: 35047–35052.
Wexler L, Thiele CJ, McClure L, Chanock S, Mertins S, Tsokos M et al. (1992). Adoptive immunotherapy of refractory neuroblastoma with tumor-infiltrating lymphocytes, interferon-{gamma}, and interleukin-2. Proc Ann Meet Am Soc Clin Oncol 11: 368.
Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U et al. (2003). Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63: 1122–1129.
Acknowledgements
We thank R Agami (The Netherlands Cancer Institute, Amsterdam, Netherlands) for providing pRETRO-SUPER vector, CA Schmitt (Berlin, Germany) for mouse Bcl-2 vector, M. Romani (Genova, Italy) for caspase-8 pBL-CAT3 promoter construct, Apoxis (Lausanne, Switzerland) for mega-Fas ligand and F Beguinot (Naples, Italy) for anti-PED antibody. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, IAP6/18 and the European Community (ApopTrain, APO-SYS) (to SF).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Häcker, S., Dittrich, A., Mohr, A. et al. Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28, 3097–3110 (2009). https://doi.org/10.1038/onc.2009.161
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/onc.2009.161
Keywords
This article is cited by
-
Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation
Molecular Biology Reports (2022)
-
BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis
Oncogene (2018)
-
DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells
Oncogene (2018)
-
Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death
Cell Death & Disease (2017)
-
A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis
Cell Death & Differentiation (2017)


